Skip to main content

Advertisement

Figure 2 | Journal of Translational Medicine

Figure 2

From: Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer

Figure 2

Peptide specific CTL response in case 9. Strong CTL responses specific to KIF20A-66 peptide were obtained at the time of 2 months after vaccination. The responses were kept strong positive during 2 years of the observation period. The number of the spots specific to peptide was calculated by subtracting the spot number in control wells from that in peptide-pulsed TISI cells.

Back to article page